Company intelligence / Profile preview
Bioheng Therapeutics
Nanjing, Jiangsu, Chinabioheng.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Bioheng’s lead universal allogeneic CAR-T program targeting CD7 has demonstrated strong safety and efficacy signals. In a recent Phase I trial for relapsed/refractory T-cell ALL/LBL, the product RD13‑02 achieved response rates up to 92% with robust persistence data. The company’s sequential therapy approach combining UCAR-T with allogeneic HSCT was published in the New England Journal of Medicine. Their IND application for CTD402 was cleared by the FDA in February/March 2025 to proceed into a global Phase Ib/II trial.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Allogeneic CAR-T (UCAR-T)Gene-edited cell therapy (CRISPR/Cas9 and proprietary Cas-V2)Viral vector-based therapiesImmunotherapy
- Industry
- Biotech
02
Drug pipeline
13 assets12 more assets in the full pipeline.
03
Partnerships
Hillhouse CapitalDecheng CapitalOctagon Capital PartnersSimcere PharmaceuticalKACTUS
Beyond the preview
Go deeper on Bioheng Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bioheng Therapeutics.